Biotech M&A Roars Back: Why 2026 Is Already the Best Dealmaking Year in Seven Years 4 weeks ago AnaIn Featured AnalysisPartnershipsTop StoriesVenture Capital
Bausch + Lomb Discontinues Glaucoma Eye Drop Program After Phase 2 Trial Misses Primary Endpoint 4 weeks ago AnaIn Clinical TrialsPharma Industry Updates
Q32 Bio Reports 36-Week Data From Expanded Alopecia Areata Trial, Advancing Bempikibart Toward Pivotal Studies 4 weeks ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisTop Stories
Vaccinex Reports New Glial Biomarker Data for Pepinemab, Outlines Path to Expanded Phase 2b Alzheimer’s Study 4 weeks ago AnaIn Deals
Beyond Amyloid: AAIC 2026 Signals a Broader, More Testable Alzheimer’s Pipeline 4 weeks ago AnaIn Clinical TrialsFeatured AnalysisIndustry ConferencesResearch Updates
Celea Therapeutics Launches With $180 Million to Challenge Pirfenidone in IPF 1 month ago AnaIn DealsFunding RoundsResearch UpdatesStartups
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy for Australian Market 1 month ago AnaIn BreakthroughsResearch Updates
Epcoritamab Clears Phase 3 Bar in Relapsed Large B-Cell Lymphoma 1 month ago AnaIn Clinical TrialsPartnershipsResearch Updates
Vertex’s Casgevy Clears FDA Hurdle for Youngest Sickle Cell Patients 1 month ago AnaIn Breaking NewsBreakthroughsFDA ApprovalsPartnerships
No Single Mechanism Solves Epilepsy: What Bright Minds’ BMB-101 Data Tells Us About the Future of Seizure Control 1 month ago AnaIn AI & DataFeatured AnalysisLeadersPeopleResearch Updates
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy Altuviiio, Widening Treatment Options for Australian Patients 1 month ago AnaIn BreakthroughsClinical TrialsPharma Industry UpdatesTop Stories
Slate Medicines Emerges With $130 Million to Chase PACAP, a Migraine Target Distinct From CGRP 1 month ago AnaIn DealsFunding RoundsInnovationInvestments
FDA Extends Casgevy’s Reach to Children as Young as Two, Reshaping the Sickle Cell Treatment Landscape 1 month ago AnaIn Breaking NewsFDA ApprovalsInnovationPharma Industry Updates
Orca Bio’s Tregzi Wins FDA Approval as First Regulatory T-Cell Therapy to Curb Chronic Graft-Versus-Host Disease 1 month ago AnaIn BreakthroughsFDA ApprovalsFeatured AnalysisResearch Updates
Epcoritamab Combination Hits Progression-Free Survival Mark in Phase 3 Lymphoma Trial, Genmab and AbbVie Report 1 month ago AnaIn BreakthroughsClinical TrialsPartnershipsResearch Updates
